deepCDR Biologic's proprietary mammalian display platform:
Pogson, M. et al. Immunogenomic engineering of a plug-and-(dis)play hybridoma platform. Nat. Commun. 7:12535 doi: 10.1038/ncomms12535 (2016).
Antibody engineering in our mammalian display platform:
Derek M Mason, Cédric R Weber, Cristina Parola, Simon M Meng, Victor Greiff, William J Kelton, Sai T Reddy, High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis, Nucleic Acids Research, Volume 46, Issue 14, 21 August 2018, Pages 7436–7449,
Expanding antibody optimization with in our mammalian cell platform with deep learning:
Mason,D.M., Friedensohn,S., Weber,C.R., Jordi,C., Wagner,B., Meng,S., Gainza,P., Correia,B.E. and Reddy,S.T. (2019) Deep learning enables therapeutic antibody optimization in mammalian cells by deciphering high-dimensional protein sequence space. bioRxiv, 10.1101/617860.
De novo antibody discovery using our mammalian display platform:
Parola, C., Neumeier, D., Friedensohn, S., Csepregi, L., Di Tacchio, M., Mason, D. M., & Reddy, S. T. (2019, November). Antibody discovery and engineering by enhanced CRISPR-Cas9 integration of variable gene cassette libraries in mammalian cells. In mAbs (Vol. 11, No. 8, pp. 1367-1380). Taylor & Francis.
<Insert caption highlight paper here>[Leave this blank for now]
Friedensohn, S., Neumeier, D., Khan, T. A., Csepregi, L., Parola, C., de Vries, A. R. G., ... & Reddy, S. T. (2020). Convergent selection in antibody repertoires is revealed by deep learning. bioRxiv.